Analyst Ratings For Endocyte (NASDAQ:ECYT)
Today, Endocyte (NASDAQ:ECYT) stock received an upgrade by Cowen from Market Perform to Outperform.
Some recent analyst ratings include
- 2/27/2018-Cowen Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 10/3/2017-Wedbush Upgrade from a “Neutral ” rating to a ” Outperform” rating.
- 11/11/2016-Credit Suisse Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Endocyte (NASDAQ:ECYT)
Endocyte (NASDAQ:ECYT) has insider ownership of 14.86% and institutional ownership of 19.45%.
- On 12/28/2017 Philip S Low, Insider, sold 50,511 with an average share price of $4.41 per share and the total transaction amounting to $222,753.51.
- On 12/28/2017 Philip S Low, Insider, sold 50,511 with an average share price of $4.41 per share and the total transaction amounting to $222,753.51.
- On 12/1/2017 Christopher P Leamon, VP, sold 23,231 with an average share price of $5.04 per share and the total transaction amounting to $117,084.24.
- On 11/13/2017 Philip S Low, Insider, bought 5,600 with an average share price of $4.84 per share and the total transaction amounting to $27,104.00.
- On 12/30/2016 Christopher P. Leamon, VP, sold 23,244 with an average share price of $2.55 per share and the total transaction amounting to $59,272.20.
- On 5/10/2016 Philip S Low, Insider, bought 11,375 with an average share price of $3.52 per share and the total transaction amounting to $40,040.00.
- On 1/19/2016 Fred A. Middleton, Director, bought 10,000 with an average share price of $2.79 per share and the total transaction amounting to $27,900.00.
Recent Trading Activity for Endocyte (NASDAQ:ECYT)
Shares of Endocyte closed the previous trading session at 4.29 up +0.04 0.94% with 4.5 shares trading hands.